Followers | 283 |
Posts | 1162 |
Boards Moderated | 0 |
Alias Born | 10/04/2020 |
Monday, September 20, 2021 1:38:09 AM
Isn't it interesting that BLARING "little fact" you mentioned somehow got "OVERLOOKED" How convenient! LOL!
Post 9/28/21 there will emerge an ALL NEW OTC that like you said, with about an 85% elimination of Stocks due to SEC Non-Compliance!
What that means of course is MONEY will naturally flow into stocks with the lowest risk, i.e. those that have real business operations, valuable products and/or services, a high market demand, established partnerships, and revenue or eminently positioned for revenue.
RGBP has ALL of these elements AND a looming potential Buy Out that most everyone knows about by now based on the 8K Dr. Koos filed on 4/27/21 that protects against a Hostile Take Over during Negotiations to ACQUIRE RGBP. There's just no getting past this!
I would like to see anyone name a single OTC that's Pink Current AND has the potential of RGBP in the same sector, keeping in mind that this company has a Patent Portfolio worth Billions that includes an mRNA Vaccine Patent that was recently licensed to Oncology Pharma who paid $1.1 Million Dollars for those rights.
Here's something interesting that came out on 9/13/21 that reveals the extraordinary value of mRNA Vaccine Patents.
A Chinese Bio-Pharma Everest Medicine just cut a check for $500 MILLION DOLLARS to license an mRNA Covid-19 Vaccine Patent from Canada’s Providence Therapeutics Holdings Inc.
https://www.bloomberg.com/news/articles/2021-09-13/chinese-firm-buys-canada-mrna-vaccine-tech-in-500-million-deal
Again, a Half Billion Dollars just to LICENSE that single Patent, nothing else!
Well RGBP has the exact same Class Patent, not to mention the other 23 Patents it has that represent Disruptive Biotechnology, each worth Billions:
https://patents.google.com/?inventor=David+Koos&sort=new
Again what other OTC Bio Pharma has these elements AND is positioned to receive Quarterly Revenues for 15 Years based on its licensing arrangement with Oncology Pharma? Here's how many: NONE!!
Great call!
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM